🎮 DEMO PLAYGROUND - Sample data for demonstration purposes
Risk Dashboard
Centralized risk monitoring across 6 active trials
Min Score:
Showing 11 of 11 risks
| SCORE | TRIAL | CATEGORY | DESCRIPTION | PROBABILITY | IMPACT | OWNER | |
|---|
25 | RESPI-CLEAR-4 | ENROLLMENT | Extremely high screen failure rate due to restrictive spirometry criteria Mitigation: Emergency protocol amendment requested to relax FEV1 criteria | 5/5 | 5/5 | Dr. Emily Rodriguez | |
20 | NEURO-PATH-7 | ENROLLMENT | Screen failure rate significantly above benchmark Mitigation: Revise inclusion criteria with sponsor; add cognitive screening pre-consent | 5/5 | 4/5 | Dr. Sarah Chen | |
20 | RESPI-CLEAR-4 | BUDGET | Study may not complete on time or budget Mitigation: Sponsor reviewing feasibility; may close site or amend protocol | 5/5 | 4/5 | Finance Team | |
16 | NEURO-PATH-7 | BUDGET | Budget overrun due to extended enrollment period Mitigation: Negotiate budget amendment with sponsor | 4/5 | 4/5 | Finance Team | |
16 | RESPI-CLEAR-4 | OPERATIONAL | Single site creates enrollment bottleneck Mitigation: Proposal to add Memphis site as backup location | 4/5 | 4/5 | Dr. Emily Rodriguez | |
12 | APEX-301 | ENROLLMENT | Chattanooga site enrollment velocity below target Mitigation: Increase patient referral network and marketing budget | 4/5 | 3/5 | Dr. Michael Park | |
9 | CARDIO-SHIELD-2 | ENROLLMENT | Competing trial opened at nearby academic center Mitigation: Expand referral network to community cardiology practices | 3/5 | 3/5 | Dr. James Mitchell | |
9 | NEURO-PATH-7 | OPERATIONAL | Staff turnover at Memphis site impacting enrollment Mitigation: Hire additional coordinator; cross-train Nashville staff | 3/5 | 3/5 | Dr. James Mitchell | |
8 | APEX-301 | REGULATORY | Protocol amendment may impact budget and timeline Mitigation: Reserve 10% contingency budget for amendments | 2/5 | 4/5 | Sarah Chen | |
6 | ONCO-BRIDGE-9 | ENROLLMENT | Dose escalation may slow enrollment if toxicity observed Mitigation: Build buffer time into enrollment projections | 3/5 | 2/5 | Dr. Sarah Chen | |
4 | METABOFIX-1 | ENROLLMENT | New diabetes medication approved; may impact recruitment Mitigation: Monitor enrollment velocity; expand eligibility to include patients on standard care | 2/5 | 2/5 | Dr. Michael Park | |